Telbiwudyna (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Telbiwudyna" in Polish language version.

refsWebsite

Global rank Polish rank

10nih.gov

4^th place

7^th place

8doi.org

2^nd place

6^th place

doi.org

Lai CL., Leung N., Teo EK., Tong M., Wong F., Hann HW., Han S., Poynard T., Myers M., Chao G., Lloyd D., Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. „Gastroenterology”. 2 (129), s. 528–536, sierpień 2005. DOI: 10.1016/j.gastro.2005.05.053. PMID: 16083710.
Lai CL., Gane E., Liaw YF., Hsu CW., Thongsawat S., Wang Y., Chen Y., Heathcote EJ., Rasenack J., Bzowej N., Naoumov NV., Di Bisceglie AM., Zeuzem S., Moon YM., Goodman Z., Chao G., Constance BF., Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. „The New England journal of medicine”. 25 (357), s. 2576–2588, grudzień 2007. DOI: 10.1056/NEJMoa066422. PMID: 18094378.
Nash K. Telbivudine in the treatment of chronic hepatitis B. „Advances in therapy”. 2 (26), s. 155–169, luty 2009. DOI: 10.1007/s12325-009-0004-y. PMID: 19225726.
Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. „AIDS (London, England)”. 4 (23), s. 546–547, luty 2009. DOI: 10.1097/QAD.0b013e3283262f09. PMID: 19240461.
Liaw YF., Gane E., Leung N., Zeuzem S., Wang Y., Lai CL., Heathcote EJ., Manns M., Bzowej N., Niu J., Han SH., Hwang SG., Cakaloglu Y., Tong MJ., Papatheodoridis G., Chen Y., Brown NA., Albanis E., Galil K., Naoumov NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. „Gastroenterology”. 2 (136), s. 486–495, luty 2009. DOI: 10.1053/j.gastro.2008.10.026. PMID: 19027013.
Hou J., Yin YK., Xu D., Tan D., Niu J., Zhou X., Wang Y., Zhu L., He Y., Ren H., Wan M., Chen C., Wu S., Chen Y., Xu J., Wang Q., Wei L., Chao G., Constance BF., Harb G., Brown NA., Jia J. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. „Hepatology (Baltimore, Md.)”. 2 (47), s. 447–454, luty 2008. DOI: 10.1002/hep.22075. PMID: 18080339.
Bridges EG., Selden JR., Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. „Antimicrobial agents and chemotherapy”. 7 (52), s. 2521–2528, lipiec 2008. DOI: 10.1128/AAC.00029-08. PMID: 18474576.
Bailon P., Won CY. PEG-modified biopharmaceuticals. „Expert opinion on drug delivery”. 1 (6), s. 1–16, styczeń 2009. DOI: 10.1517/17425240802650568. PMID: 19236204.

nih.gov

ncbi.nlm.nih.gov

Lai CL., Leung N., Teo EK., Tong M., Wong F., Hann HW., Han S., Poynard T., Myers M., Chao G., Lloyd D., Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. „Gastroenterology”. 2 (129), s. 528–536, sierpień 2005. DOI: 10.1016/j.gastro.2005.05.053. PMID: 16083710.
Lai CL., Gane E., Liaw YF., Hsu CW., Thongsawat S., Wang Y., Chen Y., Heathcote EJ., Rasenack J., Bzowej N., Naoumov NV., Di Bisceglie AM., Zeuzem S., Moon YM., Goodman Z., Chao G., Constance BF., Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. „The New England journal of medicine”. 25 (357), s. 2576–2588, grudzień 2007. DOI: 10.1056/NEJMoa066422. PMID: 18094378.
Chan HL., Heathcote EJ., Marcellin P., Lai CL., Cho M., Moon YM., Chao YC., Myers RP., Minuk GY., Jeffers L., Sievert W., Bzowej N., Harb G., Kaiser R., Qiao XJ., Brown NA. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. „Annals of internal medicine”. 11 (147), s. 745–754, grudzień 2007. PMID: 17909201.
Keam SJ. Telbivudine. „Drugs”. 13 (67), s. 1917–1929, 2007. PMID: 17722961.
Nash K. Telbivudine in the treatment of chronic hepatitis B. „Advances in therapy”. 2 (26), s. 155–169, luty 2009. DOI: 10.1007/s12325-009-0004-y. PMID: 19225726.
Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. „AIDS (London, England)”. 4 (23), s. 546–547, luty 2009. DOI: 10.1097/QAD.0b013e3283262f09. PMID: 19240461.
Liaw YF., Gane E., Leung N., Zeuzem S., Wang Y., Lai CL., Heathcote EJ., Manns M., Bzowej N., Niu J., Han SH., Hwang SG., Cakaloglu Y., Tong MJ., Papatheodoridis G., Chen Y., Brown NA., Albanis E., Galil K., Naoumov NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. „Gastroenterology”. 2 (136), s. 486–495, luty 2009. DOI: 10.1053/j.gastro.2008.10.026. PMID: 19027013.
Hou J., Yin YK., Xu D., Tan D., Niu J., Zhou X., Wang Y., Zhu L., He Y., Ren H., Wan M., Chen C., Wu S., Chen Y., Xu J., Wang Q., Wei L., Chao G., Constance BF., Harb G., Brown NA., Jia J. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. „Hepatology (Baltimore, Md.)”. 2 (47), s. 447–454, luty 2008. DOI: 10.1002/hep.22075. PMID: 18080339.
Bridges EG., Selden JR., Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. „Antimicrobial agents and chemotherapy”. 7 (52), s. 2521–2528, lipiec 2008. DOI: 10.1128/AAC.00029-08. PMID: 18474576.
Bailon P., Won CY. PEG-modified biopharmaceuticals. „Expert opinion on drug delivery”. 1 (6), s. 1–16, styczeń 2009. DOI: 10.1517/17425240802650568. PMID: 19236204.